FARMINGDALE, N.Y., April 4, 2016 /PRNewswire/ — Misonix, Inc. (MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced the launch of its newest addition to the SonicOne® platform, SonicVac™. This is the first time that the removal of debris and infected tissues is combined with ultrasonic wound debridement.
Recently released data demonstrated that ultrasonic wound debridement has value in preparing for grafting and in reducing bacterial load to aid wound healing. The addition of vacuum assistance increases the SonicOne O.R.’s ability to remove disrupted debris from the wound. Data released at Diabetic Limb Salvage (“DLS”) Conference showed 134% more irrigate was captured during the use of SonicVac.
“The treatment of chronic wounds is a significant global healthcare problem,” said Dr. Mark S. Granick, Professor and Chief, Division of Plastic Surgery, Rutgers New Jersey Medical School. “SonicVac represents an important technological development in treating chronic wounds. SonicOne with SonicVac addresses the need to disrupt and remove unhealthy cells, layer-by-layer, from the wound allowing for maximum preservation of surrounding healthy tissue. This gives the patient’s wound the best opportunity to heal.”
Scott Ludecker, Senior Vice President of Global Sales & Marketing, commented, “The addition of SonicVac further strengthens the growing acceptance of SonicOne O.R. in the wound care marketplace. This, the second product launch in the last twelve months for the SonicOne O.R. platform, illustrates our commitment to bringing new innovative solutions to the surgeons treating this patient population. We will continue working with our global opinion leading surgeon customers to innovate around our SonicOne O.R. platform technologies wherever possible.”
“The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that enables surgeons to address the challenges in treating chronic wounds. SonicOne O.R. is establishing a new standard in surgical wound bed preparation, an essential first step in the wound healing process, and we are encouraged by the growing acceptance of this technology in operating rooms around the country,” added Michael A. McManus Jr., President and Chief Executive Officer of Misonix.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Joe Diaz & Lytham Partners
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/misonix-launches-new-vacuum-assisted-ultrasonic-wound-debridement-technology-at-diabetic-limb-salvage-conference-in-washington-dc-300245366.html